These findings not only shed new light on the gut–brain interactions involved in ADT‐associated neurotoxicity but also suggest that targeting bile acid metabolism and TGR5 signaling may represent a promising therapeutic strategy to mitigate cognitive impairment in prostate cancer patients undergoing ADT. This evidence concerns the gene GPBAR1 and prostate cancer.